These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29700392)

  • 1. EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.
    Toosi BM; El Zawily A; Truitt L; Shannon M; Allonby O; Babu M; DeCoteau J; Mousseau D; Ali M; Freywald T; Gall A; Vizeacoumar FS; Kirzinger MW; Geyer CR; Anderson DH; Kim T; Welm AL; Siegel P; Vizeacoumar FJ; Kusalik A; Freywald A
    Oncogene; 2018 Jul; 37(30):4073-4093. PubMed ID: 29700392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation.
    El Zawily AM; Toosi BM; Freywald T; Indukuri VV; Vizeacoumar FJ; Leary SC; Freywald A
    Oncotarget; 2016 Nov; 7(47):77865-77877. PubMed ID: 27788485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.
    Paul JM; Toosi B; Vizeacoumar FS; Bhanumathy KK; Li Y; Gerger C; El Zawily A; Freywald T; Anderson DH; Mousseau D; Kanthan R; Zhang Z; Vizeacoumar FJ; Freywald A
    Oncotarget; 2016 Aug; 7(31):50027-50042. PubMed ID: 27418135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of liver-intestine cadherin (Cadherin 17) expression, ERK phosphorylation and WNT signaling in EPHB6 receptor-expressing MDA-MB-231 cells.
    Bhushan L; Tavitian N; Dey D; Tumur Z; Parsa C; Kandpal RP
    Cancer Genomics Proteomics; 2014; 11(5):239-49. PubMed ID: 25331796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.
    He J; Lee HJ; Saha S; Ruan D; Guo H; Chan CH
    Cell Death Dis; 2019 Mar; 10(4):285. PubMed ID: 30918246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer.
    Stratford AL; Reipas K; Maxwell C; Dunn SE
    Expert Rev Mol Med; 2010 Jul; 12():e22. PubMed ID: 20653987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells.
    Truitt L; Freywald T; DeCoteau J; Sharfe N; Freywald A
    Cancer Res; 2010 Feb; 70(3):1141-53. PubMed ID: 20086179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options.
    Burnett JP; Korkaya H; Ouzounova MD; Jiang H; Conley SJ; Newman BW; Sun L; Connarn JN; Chen CS; Zhang N; Wicha MS; Sun D
    Sci Rep; 2015 Nov; 5():15821. PubMed ID: 26522776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression.
    Wu JE; Wu YY; Tung CH; Tsai YT; Chen HY; Chen YL; Hong TM
    Theranostics; 2020; 10(19):8903-8923. PubMed ID: 32754286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand stimulation induces clathrin- and Rab5-dependent downregulation of the kinase-dead EphB6 receptor preceded by the disruption of EphB6-Hsp90 interaction.
    Allonby O; El Zawily AM; Freywald T; Mousseau DD; Chlan J; Anderson D; Benmerah A; Sidhu V; Babu M; DeCoteau J; Freywald A
    Cell Signal; 2014 Dec; 26(12):2645-57. PubMed ID: 25152371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-Positive Breast Cancer Following Endocrine Therapy.
    Peiffer DS; Wyatt D; Zlobin A; Piracha A; Ng J; Dingwall AK; Albain KS; Osipo C
    Cancer Res; 2019 Oct; 79(19):4965-4977. PubMed ID: 31387918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A paradigm shift in EPH receptor interaction: biological relevance of EPHB6 interaction with EPHA2 and EPHB2 in breast carcinoma cell lines.
    Fox BP; Kandpal RP
    Cancer Genomics Proteomics; 2011; 8(4):185-93. PubMed ID: 21737611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
    Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
    Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
    Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
    Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CSC in a Most Aggressive Subtype of Breast Cancer TNBC.
    Bao B; Prasad AS
    Adv Exp Med Biol; 2019; 1152():311-334. PubMed ID: 31456192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.
    Damelin M; Bankovich A; Park A; Aguilar J; Anderson W; Santaguida M; Aujay M; Fong S; Khandke K; Pulito V; Ernstoff E; Escarpe P; Bernstein J; Pysz M; Zhong W; Upeslacis E; Lucas J; Lucas J; Nichols T; Loving K; Foord O; Hampl J; Stull R; Barletta F; Falahatpisheh H; Sapra P; Gerber HP; Dylla SJ
    Clin Cancer Res; 2015 Sep; 21(18):4165-73. PubMed ID: 26015513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.